已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

医学 肥厚性心肌病 安慰剂 内科学 心脏病学 临床终点 心肌病 心室流出道 心力衰竭 随机对照试验 病理 替代医学
作者
Iacopo Olivotto,Artur Oręziak,Roberto Barriales‐Villa,Theodore P. Abraham,Ahmad Masri,Pablo García‐Pavía,Sara Saberi,Neal K. Lakdawala,Matthew T. Wheeler,Anjali Owens,Miloš Kubánek,Wojciech Wojakowski,Juan R. Gimeno,K. Afshar,Jonathan Myers,Sheila M. Hegde,Scott D. Solomon,Amy J. Sehnert,David Zhang,Wanying Li,Mondira Bhattacharya,Jay M. Edelberg,Cynthia Burstein Waldman,Andrew Wang,Andrew Wang,Carolyn Y. Ho,Daniel Jacoby,Jozef Bartúnek,Antoine Bondue,Emeline M. Van Craenenbroeck,David Zemánek,Morten K. Jensen,Jens Mogensen,Jens Jakob Thune,Philippe Charron,Antoine Lafont,Olivier Lairez,Jean‐Noël Trochu,Christoph Axthelm,Hans‐Dirk Duengen,Norbert Frey,Veselin Mitrović,Michael Preusch,Jeanette Schulz‐Menger,Tim Seidler,Michael Arad,Majdi Halabi,Amos Katz,Daniel Monakier,Offir Paz,Samuel Viskin,Donna R. Zwas,Hans‐Peter Brunner‐La Rocca,Michelle Michels,Dariusz Dudek,Zofia Oko‐Sarnowska,Nuno Cardim,Hélder Pereira,Pablo García Pavía,Juan Gimeno Blanes,Rafael Hidalgo Urbano,Luis Alonso-Pulpón,Perry Elliott,Zaheer Yousef,Paulino Alvarez,Richard G. Bach,Richard C. Becker,Lubna Choudhury,David Fermin,John L. Jefferies,Christopher M. Kramer,Ali J. Marian,Matthew J. Maurer,Sherif F. Nagueh,David S. Owens,Florian Rader,Mark V. Sherrid,Jamshid Shirani,John D. Symanski,Aslan T. Turer,Omar Wever‐Pinzon,Timothy C. Wong,Mohamad H. Yamani
出处
期刊:The Lancet [Elsevier]
卷期号:396 (10253): 759-769 被引量:642
标识
DOI:10.1016/s0140-6736(20)31792-x
摘要

Background Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction. Available pharmacological options for hypertrophic cardiomyopathy are inadequate or poorly tolerated and are not disease-specific. We aimed to assess the efficacy and safety of mavacamten, a first-in-class cardiac myosin inhibitor, in symptomatic obstructive hypertrophic cardiomyopathy. Methods In this phase 3, randomised, double-blind, placebo-controlled trial (EXPLORER-HCM) in 68 clinical cardiovascular centres in 13 countries, patients with hypertrophic cardiomyopathy with an LVOT gradient of 50 mm Hg or greater and New York Heart Association (NYHA) class II–III symptoms were assigned (1:1) to receive mavacamten (starting at 5 mg) or placebo for 30 weeks. Visits for assessment of patient status occurred every 2–4 weeks. Serial evaluations included echocardiogram, electrocardiogram, and blood collection for laboratory tests and mavacamten plasma concentration. The primary endpoint was a 1·5 mL/kg per min or greater increase in peak oxygen consumption (pVO2) and at least one NYHA class reduction or a 3·0 mL/kg per min or greater pVO2 increase without NYHA class worsening. Secondary endpoints assessed changes in post-exercise LVOT gradient, pVO2, NYHA class, Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS), and Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness-of-Breath subscore (HCMSQ-SoB). This study is registered with ClinicalTrials.gov, NCT03470545. Findings Between May 30, 2018, and July 12, 2019, 429 adults were assessed for eligibility, of whom 251 (59%) were enrolled and randomly assigned to mavacamten (n=123 [49%]) or placebo (n=128 [51%]). 45 (37%) of 123 patients on mavacamten versus 22 (17%) of 128 on placebo met the primary endpoint (difference +19·4%, 95% CI 8·7 to 30·1; p=0·0005). Patients on mavacamten had greater reductions than those on placebo in post-exercise LVOT gradient (−36 mm Hg, 95% CI −43·2 to −28·1; p<0·0001), greater increase in pVO2 (+1·4 mL/kg per min, 0·6 to 2·1; p=0·0006), and improved symptom scores (KCCQ-CSS +9·1, 5·5 to 12·7; HCMSQ-SoB −1·8, −2·4 to −1·2; p<0·0001). 34% more patients in the mavacamten group improved by at least one NYHA class (80 of 123 patients in the mavacamten group vs 40 of 128 patients in the placebo group; 95% CI 22·2 to 45·4; p<0·0001). Safety and tolerability were similar to placebo. Treatment-emergent adverse events were generally mild. One patient died by sudden death in the placebo group. Interpretation Treatment with mavacamten improved exercise capacity, LVOT obstruction, NYHA functional class, and health status in patients with obstructive hypertrophic cardiomyopathy. The results of this pivotal trial highlight the benefits of disease-specific treatment for this condition. Funding MyoKardia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
程风破浪完成签到,获得积分10
1秒前
乐乐发布了新的文献求助10
4秒前
5秒前
二牛完成签到,获得积分10
5秒前
危机的囧完成签到,获得积分10
6秒前
科研人完成签到 ,获得积分10
7秒前
10秒前
赎罪完成签到 ,获得积分10
12秒前
zzzyyy应助jianrobsim采纳,获得10
14秒前
科研通AI2S应助YYJ采纳,获得10
17秒前
不知道叫个啥完成签到 ,获得积分0
19秒前
Yziii应助伊倾采纳,获得10
21秒前
高屋建瓴完成签到,获得积分10
23秒前
称心的语梦完成签到,获得积分10
23秒前
24秒前
26秒前
26秒前
27秒前
小晖晖完成签到,获得积分10
27秒前
leserein完成签到,获得积分10
28秒前
28秒前
29秒前
科研小白牛牛完成签到 ,获得积分10
29秒前
生动的发带完成签到 ,获得积分10
30秒前
得了道的小神仙完成签到 ,获得积分10
30秒前
江上游完成签到 ,获得积分10
31秒前
Halo发布了新的文献求助200
31秒前
小王想要飞完成签到 ,获得积分10
34秒前
思源应助成就的书包采纳,获得10
34秒前
EmmaEmma发布了新的文献求助30
35秒前
amber完成签到 ,获得积分10
36秒前
37秒前
大模型应助Hao采纳,获得10
37秒前
糖加三勺完成签到 ,获得积分10
41秒前
Halo完成签到,获得积分10
42秒前
碳酸芙兰完成签到,获得积分10
42秒前
48秒前
仁爱水香完成签到,获得积分10
48秒前
研友_VZG7GZ应助科研通管家采纳,获得10
50秒前
eternity136应助科研通管家采纳,获得10
50秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3136919
求助须知:如何正确求助?哪些是违规求助? 2787893
关于积分的说明 7783734
捐赠科研通 2443946
什么是DOI,文献DOI怎么找? 1299534
科研通“疑难数据库(出版商)”最低求助积分说明 625464
版权声明 600954